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In 2016, an estimated 19.5 million infants worldwide did not receive routine life-saving vaccinations according to 
the World Health Organization (WHO)1. Two major limitations in improving global vaccination coverage include 
the costs associated with vaccine manufacturing and the challenges associated with maintaining a consistent 
supply. The aim of the ‘ULTRA’ project (Ultra Low-cost TRansferable Automated Platform for Vaccine 
Manufacturing) is to standardize the development and production of new protein subunit vaccine candidates at 
globally affordable costs by creating a generic, low-cost, integrated, and automated vaccine manufacturing 
platform. In a collaborative effort between MIT, UCL, and KU (Figure 1), state-of-the-art analytical tools will be 
utilized to provide well-characterized vaccine bulk and drug product 
facilitating process changes and reduced QC costs. Additionally, to 
ensure the stability and potency of vaccines during production, storage, 
transport and administration to people in the developing world, vaccines 
will be formulated with stabilizers/adjuvants/preservatives in a multi-dose 
presentation to further assist in the development of low-cost vaccines. 
The initial candidate for the ULTRA platform is a subunit vaccine against 
rotavirus containing three recombinant non-replicating rotavirus (NRRV) 
protein antigens, P2-VP8-P[4], P2-VP8-P[6], and P2-VP8-P[8]. These 
protein antigens are currently being developed clinically by PATH with 
antigens expressed in E. coli 2. Under ULTRA, these NRRV antigens are 
being produced in Pichia pastoris. Primary structure and post-
translational modification analysis of the first generation Pichia NRRV 
strains using SDS-PAGE and LC-MS approaches (intact mass and 
peptide mapping) revealed the presence of intact protein antigen along 
with certain levels of N-terminal truncation variants, N-linked glycosylation, and protein aggregation. These 
analytical observations have guided a ‘quality-by-design’ approach to introduce site-specific modifications in 
NRRV antigens to minimize N-terminal truncations, glycosylation and reduce aggregation. Further, given the 
known compatibility issues of NRRV antigens with preservatives and limited binding to aluminum adjuvants (see 
our collaborative poster with PATH), a ‘fast-to-formulate (F2F)’ direction has been undertaken to engineer 
variants of NRRV antigens with potentially improved solubility and stability, especially in the presence of 
preservatives required for multi-dose formulations. High throughput analytical assays utilizing small amounts of 
material (~0.5 mg) to provide maximal information on antigen structure, relative solubility, and antibody binding 
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Collaborators on the ULTRA team:  
(From MIT) J. Christopher Love, Kerry R. Love, Joseph R. Brady, Neil C. Dalvie, Laura Crowell  
(From UCL) Tarit K. Mukhopadhyay, Stephen A. Morris, Lourdes Velez-Suberbie, Shaleem Jacob 
 
Figure 1 – The academic team of 
The ULTRA Collaborative 
 
